2. Immunology/Inflammation
  3. PD-1/PD-L1
  4. Durvalumab

Durvalumab  (Synonyms: MEDI 4736)

Cat. No.: HY-P9919 Purity: 99.60%
COA
SDS
Technical Support

Durvalumab (MEDI 4736) is an human anti-PD-L1 monoclonal antibody. Durvalumab (MEDI4736) completely blocks the binding of PD-L1 to both PD-1 and CD80, with IC50s of 0.1 and 0.04 nM, respectively.

For research use only. We do not sell to patients.

CAS No. : 1428935-60-7

Size Price Stock Quantity
1 mg In-stock
5 mg In-stock
10 mg In-stock
25 mg In-stock
50 mg In-stock
100 mg   Get quote  
200 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 6 publication(s) in Google Scholar

Other Forms of Durvalumab:

Durvalumab Related Antibodies

Top Publications Citing Use of Products

    Durvalumab purchased from MedChemExpress. Usage Cited in: Preprints. 10 May 2022.

    Migration-focused results of ECIS tests on T98G and U87 glioblastoma cells treated with Radiation and Durvalumab. Representative plot of normalized resistance in the first 40 hours posttreatment for T98G.

    Durvalumab purchased from MedChemExpress. Usage Cited in: Preprints. 10 May 2022.

    Barrier function-focused results of ECIS tests on T98G glioblastoma cells treated with radiation and durvalumab. Representative plot of the barrier function Rb posttreatment for T98G shown.

    Durvalumab purchased from MedChemExpress. Usage Cited in: Cancer Discov. 2020 Dec;10(12):1872-1893.  [Abstract]

    4T1-hPD-L, where the basal mouse PD-L1 was knocked out followed by adding back human PD-L1 gene, and 4T1-hB7-H4 cells were orthotopically injected into the left fourth mammary fat pad and allow to grow around 100 mm3, followed by injection of Cam (25 mg/kg, i.p.) for 4 times, NGI-1 nanoparticle (10 mg/kg, i.v.) as well as PD-L1 antibody Durvalumab (5 mg/kg, i.p.) for 3 times. The tumor growth was monitored twice per week. n=8 mice per group.

    Durvalumab purchased from MedChemExpress. Usage Cited in: Cancer Discov. 2020 Dec;10(12):1872-1893.  [Abstract]

    Survival curve of the mice of the combination of Cam, NGI-1 nanoparticle and Durvalumab (5 mg/kg, i.p., 3 times). n=8 mice per group.

    Durvalumab purchased from MedChemExpress. Usage Cited in: Cancer Discov. 2020 Dec;10(12):1872-1893.  [Abstract]

    4T1-hPD-L, where the basal mouse PD-L1 was knocked out followed by adding back human PD-L1 gene, and 4T1-hB7-H4 cells were orthotopically injected into the left fourth mammary fat pad and allow to grow around 100 mm3, followed by injection of Cam (25 mg/kg, i.p.) for 4 times, NGI-1 nanoparticle (10 mg/kg, i.v.) as well as PD-L1 antibody Durvalumab (5 mg/kg, i.p.) for 3 times. Tumor tissues were subjected to the immunohistochemically staining with anti-CD8 antibody.

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Durvalumab (MEDI 4736) is an human anti-PD-L1 monoclonal antibody[1]. Durvalumab (MEDI4736) completely blocks the binding of PD-L1 to both PD-1 and CD80, with IC50s of 0.1 and 0.04 nM, respectively[2].

    Isotype

    Human IgG1 kappa
    Recommend Isotype Controls
    Species Reactivity

    Human
    IC50 & Target

    B7-H1/PD-L1/CD274
    In Vitro

    Durvalumab (0.02-20 μg/mL, 3 days) overcomes the inhibitory effect of PD-L1 on T cell activation[1].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Durvalumab Related Antibodies
    In Vivo

    Durvalumab (0.1-5 mg/kg, intraperitoneal injection, twice a week, three weeks) suppresses human tumor growth in mouse models through T cell inhibition[1].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: NOD/SCID mice with HPAC tumor, following coimplantation of primary human T cells; NOD/SCID mice with A375 tumor, following coimplantation of primary human T cells[2]
    Dosage: 5, 1, 0.1, and 0.01 mg/kg for NOD/SCID mice with HPAC tumor; 5, 1, and 0.1 mg/kg for NOD/SCID mice with A375 tumor
    Administration: Administration i.p.; twice per week; for 3 weeks
    Result: Significantly inhibited the tumor growth of both HPAC and A375 xenografts compared with an isotype-matched control antibody.
    Clinical Trial
    Gene ID

    29126  [NCBI]

    Accession
    Application

    ELISA, FACS, Functional assay
    Conjugated

    Unconjugated
    Reconsititution

    The product can be reconstituted/diluted with sterile PBS or saline.
    Molecular Weight

    146.32 kDa

    CAS No.
    Appearance

    Liquid

    Color

    Colorless to light yellow

    SMILES

    [Durvalumab]
    Formulation

    Please refer to the lot-specific COA for specific buffer information.
    Storage

    Please store the product under the recommended conditions in the Certificate of Analysis.
    Format
    • Human IgG1 kappa
    Biological Activity
    • Flow cytometry analysis of PD-L1 overexpression CHO cells labelling PD-L1 with Durvalumab at 20 nM (Red). Goat anti human IgG Fc (Alexa Fluor488) was used as the secondary antibody at 1/1000 dilution. Isotype control - human IgG (Blue). Unlabeled control - Unlabelled cells (Gray).
    Purity & Documentation

    Purity: 99.60%

    SDS (251 KB)

    COA (292 KB)

    Inhibitory Antibodies User Guide (603 KB)
    References
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Durvalumab Related Classifications

    • Molarity Calculator

    • Dilution Calculator

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass   Concentration   Volume   Molecular Weight *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
    × = ×
    C1   V1   C2   V2
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Durvalumab1428935-60-7MEDI 4736MEDI4736MEDI-4736PD-1/PD-L1PD-1/Programmed death-ligand 1Monoclonal antibodiesanti-tumorInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Requested Quantity *

    Applicant Name *

    		 

    Salutation

    Email Address *

    		 

    Phone Number *

    Department

    		 

    Organization Name *

    City

    State

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Durvalumab
    Cat. No.:
    HY-P9919
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    SAFETY DATA SHEET (SDS)

    English - EN (251 KB) Français - FR (251 KB) Deutsch - DE (251 KB) Norwegian - NO (251 KB) Español - ES (251 KB) Swedish - SV (251 KB) Italian - IT (251 KB) Korean - KR (251 KB) Portuguese - PT (251 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.